A bevy of Street analysts weigh in on Vivus' (VVUS +11%): Cowen says Qsymia has "considerably...

|By:, SA News Editor

A bevy of Street analysts weigh in on Vivus' (VVUS +11%): Cowen says Qsymia has "considerably better" efficacy over Arena's (ARNA -7.5%) Belviq. Brean Murray says the approval came clean, without any harsh restrictions. Jefferies - after initially being negative on the stock - calls the FDA decision a "major win" for the company and upgrades the shares to Underperform. Wells Fargo is a bit more cautious, saying that despite the big win, the company still faces reimbursement challenges, a restrictive distribution network, and patient compliance.